Autism & measles vaccine? 2014 study found African American males getting MMR (measles, mumps etc.) vaccine prior to 24 months of age or 36 months of age more likely to be autistic; CDC whistleblower

on MMR vaccine-autism study gains new attention after Weldon nomination pulled; but then a recent 2020 Cochrane Review in support of MMR muddies the water! Now Weldon lashes out on being pulled: "Many

people feel big Pharma actually feared me more than they feared Bobby Jr. because of my credibility and my knowledge of science," says former congressman Dave Weldon, whose CDC nomination was pulled.”

Is there fire to this smoke? What say you?

I provide some reading material (including a substack comment by ANW and Dr. Jane Ruby’s excellent Rumble “MEASLES VACCINE: BIOWEAPON OF LIVE DISEASE AND GENE MODIFICATION) to engage the debate and ask was Robert Kennedy Jr. on the right track on autism and MMR? Is there is cover up? Not just for MMR? Did Senator Bill Cassidy also order National Institutes of Health (NIH) nominee Jay Bhattacharya to not further study a possible vaccine-autism link?:

‘But it took even longer for a Centers for Disease Control and Prevention senior scientist to disclose he and colleagues withheld a "statistically significant finding" from their peer-reviewed study of autism and measles, mumps and rubella vaccination in 2004: African-American males inoculated under age 3 had an increased risk for the disorder.’

Measles-mumps-rubella vaccination timing and autism among young african american boys: a reanalysis of CDC data | Translational Neurodegeneration | Full Text

CDC whistleblower on MMR vaccine-autism study gains new attention after Weldon nomination pulled | Just The News

‘Thompson's mea culpa takes on renewed relevance in the wake of President Trump yanking Dave Weldon's nomination as CDC director last week because "he did not have the votes" in the Senate, a decision Weldon traces in part to his interest as a Republican congressman, 20 years ago, in Wakefield's lightning-rod research on MMR vaccine side effects.

Investigative journalist Jon Rappoport elaborated on the connections in a Substack essay after Weldon's nomination died.

‘"Hey Dave, now that they dumped you on the side of the road […] how about giving inquiring minds a hand?" he wrote.’

Thompson told Just the News the CDC prohibits him from answering questions without permission, including whether it subjected him to stricter conditions at any point following his 2014 statement, which said the CDC gave him a "performance-based award" after he blew the whistle, and that "I have experienced no pressure or retaliation" from the agency.

"Ask the press office," he said when asked where the CDC gag order is documented. The agency didn't respond to queries.’

The Political Economy of Autism

MEASLES VACCINE: BIOWEAPON OF LIVE DISEASE AND GENE MODIFICATION

Now look at this Cochrane review?

See the Cochrane review next and its conclusion “Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunization”:

Vaccines for measles, mumps, rubella, and varicella in children - PubMed

Abstract

‘Background: Measles, mumps, rubella, and varicella (chickenpox) are serious diseases that can lead to serious complications, disability, and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness. This is an update of a review published in 2005 and updated in 2012.

Objectives: To assess the effectiveness, safety, and long- and short-term adverse effects associated with the trivalent vaccine, containing measles, rubella, mumps strains (MMR), or concurrent administration of MMR vaccine and varicella vaccine (MMR+V), or tetravalent vaccine containing measles, rubella, mumps, and varicella strains (MMRV), given to children aged up to 15 years.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2019, Issue 5), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to 2 May 2019), Embase (1974 to 2 May 2019), the WHO International Clinical Trials Registry Platform (2 May 2019), and ClinicalTrials.gov (2 May 2019).

Selection criteria: We included randomised controlled trials (RCTs), controlled clinical trials (CCTs), prospective and retrospective cohort studies (PCS/RCS), case-control studies (CCS), interrupted time-series (ITS) studies, case cross-over (CCO) studies, case-only ecological method (COEM) studies, self-controlled case series (SCCS) studies, person-time cohort (PTC) studies, and case-coverage design/screening methods (CCD/SM) studies, assessing any combined MMR or MMRV / MMR+V vaccine given in any dose, preparation or time schedule compared with no intervention or placebo, on healthy children up to 15 years of age.

Data collection and analysis: Two review authors independently extracted data and assessed the methodological quality of the included studies. We grouped studies for quantitative analysis according to study design, vaccine type (MMR, MMRV, MMR+V), virus strain, and study settings. Outcomes of interest were cases of measles, mumps, rubella, and varicella, and harms. Certainty of evidence of was rated using GRADE.

Main results: We included 138 studies (23,480,668 participants). Fifty-one studies (10,248,159 children) assessed vaccine effectiveness and 87 studies (13,232,509 children) assessed the association between vaccines and a variety of harms. We included 74 new studies to this 2019 version of the review. Effectiveness Vaccine effectiveness in preventing measles was 95% after one dose (relative risk (RR) 0.05, 95% CI 0.02 to 0.13; 7 cohort studies; 12,039 children; moderate certainty evidence) and 96% after two doses (RR 0.04, 95% CI 0.01 to 0.28; 5 cohort studies; 21,604 children; moderate certainty evidence). The effectiveness in preventing cases among household contacts or preventing transmission to others the children were in contact with after one dose was 81% (RR 0.19, 95% CI 0.04 to 0.89; 3 cohort studies; 151 children; low certainty evidence), after two doses 85% (RR 0.15, 95% CI 0.03 to 0.75; 3 cohort studies; 378 children; low certainty evidence), and after three doses was 96% (RR 0.04, 95% CI 0.01 to 0.23; 2 cohort studies; 151 children; low certainty evidence). The effectiveness (at least one dose) in preventing measles after exposure (post-exposure prophylaxis) was 74% (RR 0.26, 95% CI 0.14 to 0.50; 2 cohort studies; 283 children; low certainty evidence). The effectiveness of Jeryl Lynn containing MMR vaccine in preventing mumps was 72% after one dose (RR 0.24, 95% CI 0.08 to 0.76; 6 cohort studies; 9915 children; moderate certainty evidence), 86% after two doses (RR 0.12, 95% CI 0.04 to 0.35; 5 cohort studies; 7792 children; moderate certainty evidence). Effectiveness in preventing cases among household contacts was 74% (RR 0.26, 95% CI 0.13 to 0.49; 3 cohort studies; 1036 children; moderate certainty evidence). Vaccine effectiveness against rubella is 89% (RR 0.11, 95% CI 0.03 to 0.42; 1 cohort study; 1621 children; moderate certainty evidence). Vaccine effectiveness against varicella (any severity) after two doses in children aged 11 to 22 months is 95% in a 10 years follow-up (rate ratio (rr) 0.05, 95% CI 0.03 to 0.08; 1 RCT; 2279 children; high certainty evidence). Safety There is evidence supporting an association between aseptic meningitis and MMR vaccines containing Urabe and Leningrad-Zagreb mumps strains, but no evidence supporting this association for MMR vaccines containing Jeryl Lynn mumps strains (rr 1.30, 95% CI 0.66 to 2.56; low certainty evidence). The analyses provide evidence supporting an association between MMR/MMR+V/MMRV vaccines (Jeryl Lynn strain) and febrile seizures. Febrile seizures normally occur in 2% to 4% of healthy children at least once before the age of 5. The attributable risk febrile seizures vaccine-induced is estimated to be from 1 per 1700 to 1 per 1150 administered doses. The analyses provide evidence supporting an association between MMR vaccination and idiopathic thrombocytopaenic purpura (ITP). However, the risk of ITP after vaccination is smaller than after natural infection with these viruses. Natural infection of ITP occur in 5 cases per 100,000 (1 case per 20,000) per year. The attributable risk is estimated about 1 case of ITP per 40,000 administered MMR doses. There is no evidence of an association between MMR immunisation and encephalitis or encephalopathy (rate ratio 0.90, 95% CI 0.50 to 1.61; 2 observational studies; 1,071,088 children; low certainty evidence), and autistic spectrum disorders (rate ratio 0.93, 95% CI 0.85 to 1.01; 2 observational studies; 1,194,764 children; moderate certainty). There is insufficient evidence to determine the association between MMR immunisation and inflammatory bowel disease (odds ratio 1.42, 95% CI 0.93 to 2.16; 3 observational studies; 409 cases and 1416 controls; moderate certainty evidence). Additionally, there is no evidence supporting an association between MMR immunisation and cognitive delay, type 1 diabetes, asthma, dermatitis/eczema, hay fever, leukaemia, multiple sclerosis, gait disturbance, and bacterial or viral infections.

Authors' conclusions: Existing evidence on the safety and effectiveness of MMR/MMRV vaccines support their use for mass immunisation.

Campaigns aimed at global eradication should assess epidemiological and socioeconomic situations of the countries as well as the capacity to achieve high vaccination coverage. More evidence is needed to assess whether the protective effect of MMR/MMRV could wane with time since immunisation.’

___

You must not wait for another catastrophic crisis (at times manufactured but we are prevented from making our own basic personal decisions or accessing needed drugs and response tools) to catch you off-guard. We must take charge and be prepared today so that we can enjoy peace of mind tomorrow.

Enter the Wellness Company as a solution and a willing participant in the health care conversation. From telemedicine, prescriptions, memberships, and supplements, TWC is leading America with alternative choices to the traditional health care model.

If you wish to give a donation to help me, you can at:

Zelle:

sr7283@gmail.com

Or Ko-Fi

Ko-fi.com/drpauleliasalexander

Or to my address at:

150 South 8th Street

Unit 170

Lewiston, New York

14092

Alternatively, please consider going from an UNPAID subscriber or follower to a PAID at $5 per month or $30 per year. This can provide me help. If this is not possible at this time, this is ok, please remain a subscriber for FREE and there is no difference between FREE and PAID. No restrictions.

Please consider support of a good PATRIOT company (in this PATRIOT economy) Drs. McCullough, Risch, Thorp, myself support (they are our sponsors), The Wellness Company; see the emergency preparation kit (key component being antibiotics you were denied by doctors, pharmacists, governments during the fraud COVID), first aid kit, travel emergency kit, contagion control kit etc. Please consider the SPIKE SUPPORT (spike protein DETOX dissolving spike from mRNA vaccine, this is critical to remove spike form the mRNA vaccine/and DNA viral vector) formula with NATTOKINASE as well as the triple formula (SPIKE SUPPORT, BROMELAIN, CIRCUMIN)